Item 8.01 Other Events.
As previously disclosed, in November 2016, Ocular Therapeutix, Inc. (the “Company”) received notice from the New England District Office of the U.S.
Food and Drug Administration (the “FDA”) accepting that the Company’s responses satisfactorily addressed the remaining corrective actions in a Form 483 originally issued by the FDA in February 2016 relating to deficiencies in the
Company’s manufacturing process and controls for its product candidate DEXTENZA.
Following a meeting with the FDA in October 2016 and receipt of the
notice from the FDA’s New England District Office in November 2016 closing out the remaining Form 483 issues, the Company has continued to prepare for a resubmission to the New Drug Application (“NDA”) for DEXTENZA for the treatment
of post-surgical ocular pain that the Company previously filed in September 2015. The Company received a Complete Response Letter from the FDA regarding the NDA for DEXTENZA in July 2016. The Company’s plan is to include manufacturing records
from recently completed commercial batches of DEXTENZA in the NDA resubmission. The NDA resubmission is expected early in the first quarter of 2017 following the completion of testing of these commercial batches.
Adequate resolution of the Form 483 manufacturing deficiencies with the FDA’s New England District Office is a prerequisite to the approval of the NDA
for DEXTENZA, although the final decision as to the adequacy of the Company’s manufacturing processes is made by the FDA’s Center for Drug Evaluation and Research, with input from the Office of Process and Facilities, as part of the NDA
review process. The Company anticipates that the FDA will classify the resubmission of the NDA and determine whether a re-inspection of the Company’s manufacturing facility is needed within 30 days of the NDA resubmission date. The Company
expects that, if the FDA makes a decision to conduct a re-inspection of the manufacturing facility, such a decision would result in a classification of the resubmission to the NDA as a class 2, or major review, and would take up to six months to
complete. If no re-inspection is required, the Company expects the FDA to classify the NDA resubmission as a class 1, or minor review, and take up to two months to complete.
Forward Looking Statements
Any statements in this filing
about future expectations, plans and prospects for the Company, including the development and regulatory status of the Company’s product candidates, such as the Company’s expectations and plans regarding regulatory submissions for and the
timing and conduct of clinical trials of DEXTENZA™ for the treatment of post-surgical ocular inflammation and pain, including our expectations regarding the NDA filed with the FDA and the resubmission of the NDA, DEXTENZA for the treatment of
allergic conjunctivitis, DEXTENZA for the treatment of inflammatory dry eye disease and OTX-TP for the treatment of glaucoma and ocular hypertension, the ongoing development of the Company’s sustained release hydrogel depot technology, the
potential utility of any of the Company’s product candidates, potential commercialization of the Company’s product candidates, the potential benefits and future operation of the collaboration with Regeneron, including any potential future
payments thereunder, the sufficiency of the Company’s cash resources and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend”, “goal,”
“may”, “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar
expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various
important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s clinical development programs, future results, performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to the timing and costs involved in commercializing ReSure
®
Sealant or
any product candidate that receives regulatory approval, the initiation and conduct of clinical trials, availability of data from clinical trials and expectations for regulatory submissions and approvals, the Company’s scientific approach and
general development progress, the availability or commercial potential of the Company’s product candidates, the sufficiency of cash resources and need for additional financing or other actions and other factors discussed in the “Risk
Factors” section contained in the Company’s reports on file with the Securities and Exchange Commission, including the Risk Factors filed on Form 8-K on November 30, 2016. In addition, the forward-looking statements included in this
report represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.